Supriya Lifescience Limited (SUPRIYA.BO)
- Previous Close
713.80 - Open
717.40 - Bid 698.65 x --
- Ask 702.40 x --
- Day's Range
696.95 - 718.15 - 52 Week Range
336.00 - 841.70 - Volume
9,462 - Avg. Volume
27,151 - Market Cap (intraday)
56.35B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
30.00 - EPS (TTM)
23.34 - Earnings Date Aug 8, 2025 - Aug 9, 2025
- Forward Dividend & Yield 0.80 (0.11%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
843.00
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
www.supriyalifescience.comRecent News: SUPRIYA.BO
View MorePerformance Overview: SUPRIYA.BO
Trailing total returns as of 6/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUPRIYA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUPRIYA.BO
View MoreValuation Measures
Market Cap
57.45B
Enterprise Value
56.70B
Trailing P/E
30.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.25
Price/Book (mrq)
5.76
Enterprise Value/Revenue
8.14
Enterprise Value/EBITDA
20.96
Financial Highlights
Profitability and Income Statement
Profit Margin
26.99%
Return on Assets (ttm)
14.77%
Return on Equity (ttm)
20.74%
Revenue (ttm)
6.96B
Net Income Avi to Common (ttm)
1.88B
Diluted EPS (ttm)
23.34
Balance Sheet and Cash Flow
Total Cash (mrq)
791.54M
Total Debt/Equity (mrq)
0.54%
Levered Free Cash Flow (ttm)
-203.5M